Overview
EvoDenovo is a US-based, preclinical-stage biotechnology company developing next-generation therapies for central nervous system (CNS) disorders. We combine precision biologics (nanobodies) and small molecules to modulate GPCR pathways implicated in stress, mood, and opioid dependence—areas where today’s options are often limited by safety, tolerability, or real-world scalability.
Our lead program, NB20, is a first-in-class intranasal nanobody targeting GPR158 (mGlyR), designed to deliver rapid, durable antidepressant-like effects in preclinical models while enabling an outpatient-friendly prescription format. In parallel, we are advancing a small-molecule program aimed at reducing opioid withdrawal and enhancing opioid analgesia, with the goal of improving pain control while lowering required opioid doses.
EvoDeNovo has received ~$3M in NIH SBIR non-dilutive funding and is actively building strategic partnerships to accelerate IND-enabling development and early clinical proof-of-concept.